Position in LYEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,493,515
-$1,485,715 QoQ
Shares Held
106,300
-28.4% QoQ
Ownership
0.434%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#20
of 87 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. LYEL ranks #157 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,493,515 | 106,300 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $2,979,230 | 148,516 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $2,256,635 | 73,315 | Shares | Other | 2026-02-13 | |
| 2025-06-30 | $93,527 | 10,580 | Shares | Other | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||